NPPA fixes retail prices of 21 formulations

NPPA has fixed retail prices of 21 formulations under Drugs Prices Control Order (DPCO)- 2013 based on its 72nd Authority meeting dated January 20, 2020.

674
NPPA Price of drugs
2 min. read

NPPA has fixed retail prices of 21 formulations under Drugs Prices Control Order (DPCO)- 2013 based on its 72nd Authority meeting dated January 20, 2020.

For notification, Click here

Name of the formulations include:

Paclitaxel + human albumin injection (Paclitaxel protein bound particles for injectable suspension 100mg),
Calcium + vitamin d3 + methylcobalamin + pyridoxine + folic acid tablet,
Ildagliptin +  metformin tablet (Insuvil-M),
Vildagliptin +  metformin tablet,
Vildagliptin +  metformin tablet (Vildov M 500),
Vildagliptin +  metformin tablet (Valdepain M 500),
Vildagliptin +  metformin tablet,
Vildagliptin +  metformin tablet (Vildov M 1000),
Vildagliptin +  metformin tablet (Valdepain M 1000),
Amoxycillin + potassium clavulanate tablet (Panlactic 1000),
Amoxycillin + potassium clavulanate tablet (Panlactic 375),
Rabies human monoclonal antibody injection (Rabishield – 50),
Amoxicillin + cloxacillin + lactic acid bacillus capsule,
Metformin hydrochloride + evogliptin tablet (Valera M 1000 tablet) and
Paracetamol + caffeine tablet (Sarbyna Strong).

The formulation for which ceiling price has been fixed is human normal immunoglobulin.

All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price as specified plus goods and services taxes applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13(2) of the DPCO 2013.

The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013.

As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

The manufacturers not complying with the ceiling price and notes specified herein above shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities (EC) Act, 1955.

Consequent to the issue of ceiling prices of such formulations as specified in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the said date of notification, stand(s) superseded, the NPPA in its notification said.

Also read another news of NPPA, Click the links below
NPPA fixes retail prices of 17 Formulations
NPPA fixes retail price of 7 drug formulations
NPPA fixes price of 2 inhaler devices
NPPA fixes retail prices of 75 formulations under DPCO 2013
NPPA fixes retail prices of 12 formulations
NPPA fixes retail prices of 21 formulations

LEAVE A REPLY

Please enter your comment!
Please enter your name here